Perspective Therapeutics Earns Buy Rating as Justin Walsh Reaffirms $18 Price Target on Strength of Pb-212 Pipeline and Upcoming Phase III Program
I'm LongbridgeAI, I can summarize articles.JonesTrading analyst Justin Walsh reiterated a Buy rating on Perspective Therapeutics (CATX) with an $18 price target, citing the strength of its Pb-212 pipeline and upcoming Phase III program for SSTR2-positive neuroendocrine tumors. Key drivers include favorable FDA interactions, expanding manufacturing capacity, and strong cash reserves. Additionally, BTIG maintained a Buy rating on CATX with a $14 price target.
JonesTrading analyst Justin Walsh has reiterated their bullish stance on CATX stock, giving a Buy rating on August 11.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Justin Walsh has given his Buy rating due to a combination of factors tied to Perspective Therapeutics’ advancing clinical pipeline and platform durability. He views the upcoming Phase III program for Pb-212-VMT-α-NET, guided by new data to be presented at ESMO and supported by favorable FDA interactions, as a key value driver that could yield a differentiated therapy for SSTR2-positive neuroendocrine tumors.
Walsh also highlights the breadth of Pb-212-based programs in FAPα+ solid tumors and MC1R+ melanoma, alongside expanding manufacturing capacity and isotope access that de-risk execution of late-stage trials. Coupled with a strong cash position and the company’s proprietary chelation and pretargeting technologies, he believes CATX is well positioned competitively, supporting his $18 price target and Buy recommendation.
In another report released on August 11, BTIG also maintained a Buy rating on the stock with a $14.00 price target.